In tumors such as hepatocellular carcinoma, gastric cancer, and breast cancer, high METTL16 expression is frequently correlated with enhanced tumor invasiveness, poor differentiation, and reduced overall survival (57). Here, METTL16 is linked to breast carcinoma.